SEP 1·SEC EDGARLow
Freidin Aaron sold $672K of GRAL
Freidin Aaron (Chief Financial Officer) sold 7,900 shares of GRAIL, Inc. (GRAL) at $85.01 ($0.67M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$GRAL
GRAIL, Inc.
Price · $GRALvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $GRAL in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.1M 2 txs
Ofman Joshua J.1× · $425K
10b5-1 share of filings100%
Top stories · $GRALMore →
AUG 15·rttnews.com
Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
AUG 13·yahoo.com
GRAIL (GRAL) Q2 2026 Earnings Call Transcript
GRAIL (GRAL) reported Q2 2026 results from its Galleri multi-cancer early detection test. The company cited PATHFINDER 2 (35,000 participants) and NHS-Galleri (140,000, three annual tests) presented at ASCO, with false positives under 0.5% and 61,000 tests sold in Q2. Q2 screening revenue was $42.6M, up 24% YoY; H1 revenue exceeded $80M. GRAIL completed a $110M financing with Samsung and is expanding internationally.
GRAL sentiment & insider activity
Recent GRAL coverage spans financial news, earnings and regulation.
In the last 30 days, GRAL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.1M). The most active reporter was Ofman Joshua J., Chief Executive Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving GRAL
Insider sell by the CFO may signal confidence concerns, modest negative pressure on GRAL.
The scheduled FDA panel review is a time-bound regulatory milestone that can increase volatility into the decision window.
Near-term trading focus is on FDA PMA progress and commercialization momentum (test volumes, partnerships, and international expansion).
The scheduled FDA advisory committee review is a near-term regulatory catalyst that can shift perceived approval odds and valuation risk for GRAL.
The filing provides fresh operating metrics, cash runway context, and a concrete regulatory timeline catalyst (FDA advisory committee in fall).
alphai scores every news story that mentions GRAL with an AI model for sentiment and relevance, and aggregates insider trades from GRAIL, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $GRAL
Score
Freidin Aaron sold $672K of GRAL
Freidin Aaron (Chief Financial Officer) sold 7,900 shares of GRAIL, Inc. (GRAL) at $85.01 ($0.67M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
1 min readWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min read
GRAIL (GRAL) Q2 2026 Earnings Call Transcript
GRAIL (GRAL) reported Q2 2026 results from its Galleri multi-cancer early detection test. The company cited PATHFINDER 2 (35,000 participants) and NHS-Galleri (140,000, three annual tests) presented at ASCO, with false positives under 0.5% and 61,000 tests sold in Q2. Q2 screening revenue was $42.6M, up 24% YoY; H1 revenue exceeded $80M. GRAIL completed a $110M financing with Samsung and is expanding internationally.
10 min read
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc. (Nasdaq: GRAL) said the FDA’s Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for the Galleri multi-cancer early detection blood test. The filing is based on PATHFINDER 2 (25,490 participants, 1-year follow-up) and NHS-Galleri (70,000+ participants).
2 min readGRAIL, Inc. (GRAL): Results of Operations and Financial Condition
GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE Exhibit 99.1 GRAIL Reports Second Quarter 2026 Financial Results Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively,
6 min read
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP said a securities fraud class action was filed against GRAIL, Inc. (NASDAQ: GRAL), alleging misleading statements about the NHS-Galleri trial design and efficacy and selective promotion of results. The firm cites a Feb. 19, 2026 disclosure that the primary endpoint was not met and follow-up likely needed to be longer, after which GRAL shares fell 50.55% in a day. Lead plaintiff deadline is Aug. 4, 2026.
4 min read
Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.
Grail (GRAL), a multi-cancer early detection test company backed early by Jeff Bezos and Bill Gates, was bought by Illumina in 2021 and spun off in 2024. Its Galleri test results from a UK NHS trial in February did not meet the primary Stage III-IV reduction endpoint, leading to a ~50% stock drop. The article cites a current price around $72 and discusses potential FDA approval and insurer coverage as key catalysts.
6 min read
GRAL Investment Deadline: GRAIL, Inc. Securities Fraud Class Action Focuses on Trial Results; Investors Notified of August 4 Court Deadline
Bleichmar Fonti & Auld LLP says a securities fraud class action was filed against GRAIL, Inc. (NASDAQ:GRAL) and executives after the company’s NHS-Galleri trial allegedly failed to support prior statements. The suit cites a ~50.55% stock drop (Feb. 19–20, 2026) and alleges violations of Exchange Act Sections 10(b) and 20(a). Investors have until Aug. 4, 2026 to seek lead-plaintiff status.
2 min readGRAIL, Inc. (GRAL): Submission of Matters to a Vote of Security Holders
GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. gral-20260618 0001699031 FALSE 0001699031 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________________ CURRENT REPORT Pursuant to Section 13 or 15
2 min read
Why Grail Could Be the Sleeper Stock Everyone's About to Notice
Grail (GRAL) develops the Galleri multi-cancer early detection blood test, which it says screens for more than 50 cancer types. The article cites positive results from NHS Galleri 2 and Pathfinder 2 presented at the 2026 ASCO meeting, including >20% reductions in stage IV diagnoses for 12 cancers and higher detection of early-stage disease. Grail is seeking FDA approval (submitted Jan. 2026) and reported a $93.2 million net loss in Q1 2026.
6 min read